| [1] |
Chen W, Zheng R, Baade PD. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| [2] |
Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence [J]. Nat Rev Clin Oncol, 2010, 7(2): 108-115.
|
| [3] |
Koppe MJ, Boerman OC, Oyen WJG. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies [J]. Ann Surg, 2006, 243(2): 212-222.
|
| [4] |
Jayne DG, Fook S, Loi C. Peritoneal carcinomatosis from colorectal cancer [J]. Br J Surg, 2002, 89(12): 1545-1550.
|
| [5] |
宋纯，张顺. 结直肠癌腹膜转移治疗策略—AJCC第八版分期的启示 [J/CD]. 中华结直肠疾病电子杂志, 2018, 7(1): 16-20.
|
| [6] |
Huang CJ, Jiang JK, Chang SC. Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women [J]. Medicine (Baltimore), 2016, 95(47): e5177.
|
| [7] |
Baratti D, Kusamura S, Deraco M. The fifth international workshop on peritoneal surface malignancy (Milan, Italy, December 4-6, 2006): methodology of disease-specific consensus [J]. J Surg Oncol, 2008, 98(4): 258-262.
|
| [8] |
Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures [J]. Ann Surg Oncol, 2015, 22(5): 1708-1715.
|
| [9] |
Soussan M, Des Guetz G, BarrauV. Comparison of FDG-PET/CT and MR with diffusion-weighted imaging for assessing peritoneal carcinomatosis from gastrointestinal malignancy [J]. Eur Radiol, 2012, 22(7): 1479-1487.
|
| [10] |
Passot G, Dumont F, GoéréD. Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE) [J]. Br J Surg, 2018, 105(6): 663-667.
|
| [11] |
中华医学会外科学分会胃肠外科学组，中华医学会外科学分会结直肠外科学组，中国抗癌协会大肠癌专业委员会, 等. 中国结直肠癌肝转移诊断和综合治疗指南(V 2018) [J/CD]. 中华结直肠疾病电子杂志, 2018, 7(4): 302-314.
|
| [12] |
Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited [J]. Nat Rev Cancer, 2003, 3(6): 453-458.
|
| [13] |
Ahmed N, Riley C, Rice G. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment [J]. Clin Exp Metastasis, 2005, 22(5): 391-402.
|
| [14] |
Suzuki HI, Kiyono K, Miyazono K. Regulation of autophagy by transforming growth factor-β (TGF-β) signaling [J]. Autophagy, 2010, 6(5): 645-647.
|
| [15] |
Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier [J]. Cancer Treat Res, 1996, 82: 53-63.
|
| [16] |
Sugarbaker PH. Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture [J]. Can J Surg, 1989, 32(3): 164-170.
|
| [17] |
Ceelen WP, Påhlman L, Mahteme H. Pharmacodynamic aspects of intraperitoneal cytotoxic therapy [J]. Cancer Treat Res, 2007, 134: 195-214.
|
| [18] |
Honoré C, Gelli M, Francoual J. Ninety percent of the adverse outcomes occur in 10% of patients: can we identify the populations at high risk of developing peritoneal metastases after curative surgery for colorectal cancer? [J]. Int J Hyperthermia, 2017, 33: 505-510.
|
| [19] |
Elias D, Gilly F, BoutitieF. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study [J]. J Clin Oncol, 2010, 28(1): 63-68.
|
| [20] |
Verwaal VJ, Bruin S, Boot H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer [J]. Ann Surg Oncol, 2008, 15(9): 2426-2432.
|
| [21] |
中国医师协会结直肠肿瘤专委会腹膜肿瘤专业委员会. 结直肠癌腹膜转移诊治中国专家意见(2017) [J/CD]. 中华结直肠疾病电子杂志, 2017, 6(5): 360-366.
|
| [22] |
TuragaK, LevineE, Barone R. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States [J]. Ann Surg Oncol, 2014, 21(5): 1501-1505.
|
| [23] |
Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy [J]. World J Gastrointest Oncol, 2010, 2(2): 109-116.
|
| [24] |
Sugarbaker PH, Mora JT, Carmignani P. Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy [J]. Oncologist, 2005, 10(2): 112-122.
|
| [25] |
Witkamp AJ, de Bree E, Kaag MM. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin [J]. Eur J Cancer, 2001, 37(8): 979-984.
|
| [26] |
Elias D, Bonnay M, Puizillou JM. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution [J]. Ann Oncol, 2002, 13(2): 267-272.
|
| [27] |
Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road? [J]. Eur J Surg Oncol, 2019, 45: 400-402.
|
| [28] |
苏昊，周海涛，王锡山. 洛铂用于结直肠癌术中腹腔灌洗化疗的近期疗效分析 [J/CD]. 中华结直肠疾病电子杂志, 2018, 7(2): 125-129.
|
| [29] |
Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures [J]. Int J Hyperthermia, 1999, 15(2): 79-107.
|
| [30] |
Van der Speeten K, Stuart OA, Mahteme H, et al. Pharmacokineticstudy of perioperative intravenous Ifosfamide [J]. Int J SurgOncol, 2011, 2011: 185092.
|
| [31] |
Zhao P, Ding Z, Tang L, et al. Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer [J]. World J Surg Oncol, 2014, 12: 403.
|
| [32] |
Bleiberg H, Vandebroek A, Deleu I. A phase II randomized study of combined infusional leucovorin sodium and 5-FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer [J]. Acta Gastroenterol Belg, 2012, 75(1): 14-21.
|
| [33] |
Vaillant JC, Nordlinger B, DeufficS. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial [J]. Ann Surg, 2000, 231(4): 449-456.
|
| [34] |
Lee S, Chen TT, Barber CL. Autocrine VEGF signaling is required for vascular homeostasis [J]. Cell, 2007, 130(4): 691-703.
|
| [35] |
Gremonprez F, Descamps B, IzmerA. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [J]. Oncotarget, 2015, 6(30): 29889-29900.
|
| [36] |
Botrel TEA, Clark LGO, PaladiniL. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis [J]. BMC Cancer, 2016, 16: 677.
|
| [37] |
Eveno C, Passot G, GoéréD. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin [J]. Ann Surg Oncol, 2014, 21(6): 1792-1800.
|
| [38] |
Regine Schneider-Stock, et al. DAPK-HSF1 interaction as a positive-feedback mechanism stimulating TNF-induced apoptosis in colorectal cancer cells [J]. Journal of Cell Science, 2014, 127: 5273-5287.
|
| [39] |
中国临床肿瘤学会抗肿瘤药物安全管理专家委员会. 重组改构人肿瘤坏死因子治疗恶性胸、腹腔积液的临床应用专家共识[J].临床肿瘤学杂志, 2018, 23(1): 67-72.
|
| [40] |
王俞，崔书中，巴明臣. 腹腔热灌注化疗联合免疫治疗在恶性腹水中的应用 [J]. 临床肿瘤学杂志, 2013, 18(11): 1041-1044.
|